×

10 biotech analysts that can make you money

Biotech
Rafe Swan | Getty Images

Editor's note: TipRanks is an independent tech company that ranks analysts and financial bloggers based on the performance of their recommendations.

Biotechnology stocks are on pace for their seventh consecutive year of gains and their run may not be over, according to some analysts.

The iShares Nasdaq Biotechnology ETF (IBB), for example, is up 13 percent this year compared with a return of 0.7 percent for the S&P 500 index.

Since biotechnology stocks are volatile in nature, analysts must be acutely aware of all FDA proceedings and clinical trials, which can make or break a stock.

Read MoreCiti's favorite stocks for 2016

So, with 2016 on the horizon, TipRanks compiled a list of the 10 best biotech analysts on Wall Street who consistently generated positive returns with their stock ratings.

The rankings are based on the following factors:

  • The average return of every recommendation given by an analyst in the year after the rating. If an analyst says "buy" Apple, the return of the call is measured in the following year.
  • The success rate of the analyst or how many of the analyst's buy/sell recommendations generated positive returns in the following year.
  • The significance of the data or how many ratings each analyst has. More ratings provide higher significance; therefore the analyst is more likely to be ranked very high or very low.

Based on more than 400,000 ratings that were measured since January 2009, here are the 10 names you must follow in 2016.

10. Rohit Vanjani, Oppenheimer

Covers biotech companies such as Insys, OvaScience and ANI Pharmaceuticals. He has been especially successful recommending shares of ANI, earning an average return of 38.5 percent on his 28 ANIP calls over the last two years. Vanjani's average return for all his buy/sell ratings is 19.8 percent. Out of his 125 total ratings, 78 have generated a positive return, resulting in a 62 percent success rate.

Contact Investing

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    Get these newsletters delivered to your inbox, and more info about about our products and service. Privacy Policy.